Illinois Medicaid Adds Second Long-Acting Atypical Antipsychotic Injection To Preferred Drug List

On April 1, 2014, Illinois Medicaid added a second long-acting injected (LAI) antipsychotic, Abilify Maintena (aripoprazole), to the preferred drug list (PDL); previously, the PDL included only one LAI, Invega Sustenna. Although on the PDL, both LAI medications require prior authorization. This change was effective on April 7, 2014.

Abilify Maintena had been a non-preferred medication on the Illinois Medicaid PDL since April 2013, shortly after the U.S. Food and Drug Administration (FDA) approved the medication in February 2013 for treatment of schizophrenia in adults. At its March 19, 2014 meeting the Illinois Department of Healthcare and . . .